Insulin Receptor
Insulin receptor (IR), a phylogenetically ancient tyrosine kinase receptor, is a large cell surface glycoprotein that concentrates insulin at the site of action and also initiates responses to insulin. The receptor is a disulfide-linked oligomer comprised of two alpha and two beta subunits. The insulin receptor exists in two isoforms, IR-A and IR-B, expressed in different relative abundance in the various organs and tissues. The two IR isoforms have similar binding affinity for insulin but different affinity for insulin-like growth factor (IGF)-2 and proinsulin, which are bound by IR-A but not IR-B.
The insulin receptor has a crucial role in controlling glucose homeostasis, regulating lipid, protein and carbohydrate metabolism, and modulating brain neurotransmitter levels. Insulin receptor dysfunction has been associated with many diseases, including diabetes, cancer and Alzheimer's disease.
All Product Categories
-
Insulin Receptor Inhibitors
(62)
View all products
-
Insulin Receptor Agonists
(34)
View all products
-
Insulin Receptor Antagonists
(12)
View all products
-
Insulin Receptor Activators
(34)
View all products
-
Insulin Receptor Modulators
(5)
View all products
-
Insulin Receptor Inducer
(1)
View all products
-
Insulin Receptor Degrader
(1)
View all products
-
Insulin Receptor Substrates
(3)
View all products
-
Insulin Receptor Ligand
(1)
View all products
-
Insulin Receptor (INSR) Proteins
(5)
View all products
-
INSR/CD220 Proteins
(7)
View all products
-
Insulin Receptor Related Products (204)
Related Products (204)
-
Recombinant Proteins (8)
-
Antibodies (8)
-
Aganirsen sodium scrambled negative control
0 ImagesCat. No.: HY-153479CAganirsen sodium scrambled negative control is the sequence scrambled negative control of Aganirsen sodium.
-
Insulin alpha-chain (1-13)
0 ImagesCat. No.: HY-P1901CAS No.: 872036-64-1Insulin alpha-chain (1-13) is a human leucocyte antigen (HLA)-DR4-restricted epitope comprising the first 13 amino acids of the insulin A-chain.
-
BDM71230
0 ImagesCat. No.: HY-182280BDM71230 is an orally active inducer of insulin-degrading enzyme (IDE), with an EC50 of 1.9 μM against human IDE. BDM71230 binds to the interface of IDE dimers and enhances the catalytic activity of IDE via steric effects. BDM71230 can potentiate the hydrolytic effect of IDE on insulin and slightly attenuate the hypoglycemic effect of insulin. BDM71230 serves as a pharmacological tool for investigating IDE function and is applicable to studies related to glucose intolerance.
-
Semaglutide sodium
0 ImagesCat. No.: HY-114118CCAS No.: 2924330-56-1Semaglutide sodium is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide sodium promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide sodium also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide sodium has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide sodium can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
-
ERK Inhibitor II (Negative control)
0 ImagesCat. No.: HY-112469CAS No.: 1177970-73-8ERK Inhibitor II (Negative control) is an effective inhibitor of extracellular signal-regulated kinase (ERK). ERK Inhibitor II (Negative control) inhibits the activation of insulin receptor, which can be used in the study of diabetes.
-
AZD9362
0 ImagesCat. No.: HY-100038CAS No.: 1905412-80-7AZD9362 is a reversible, ATP-competitive and orally active small molecule inhibitor of IGF-1R and insulin receptor. AZD9362 inhibits the IGF-1R enzyme with an IC50 of 14 nM. AZD9362 can enhance the anti-tumor effect of AZD5363 (HY-15431). AZD9362 can be used for the research of cancer, such as breast cancer.
-
LAGIPRA peptide
0 ImagesCat. No.: HY-P11285Synonyms: Long acting GIPRA-1LAGIPRA peptide is a long-acting GIP1R agonist. LAGIPRA peptide enhances insulin sensitivity by augmenting glucose disposal and reduces branched-chain amino acids (BCAAs) and ketoacids. LAGIPRA peptide has the potential for the research of type 2 diabetes.
-
Aganirsen
0 ImagesCat. No.: HY-153479CAS No.: 1146887-67-3Aganirsen is a 25 mer DNA antisense oligonucleotide, which silences expression of insulin receptor substrate-1 (IRS-1).
-
AZ-DF 265
0 ImagesCat. No.: HY-165385CAS No.: 83901-40-0
-
S-15261
0 ImagesCat. No.: HY-19176CAS No.: 159978-02-6S-15261 is an orally active and potent anti-hyperglycemic agent. S-15261 reduces hepatic glucose production through direct and insulin-sensitizing effects. S-15261 can be used for the research of insulin resistance syndrome.
-
cis-NVP-ADW742
0 ImagesCat. No.: HY-10252ACAS No.: 475489-15-7Synonyms: cis-ADW742; cis-GSK 552602A; cis-ADWcis-NVP-ADW742 (cis-ADW742) is a cis isomer of NVP-ADW742 (HY-10252). NVP-ADW742 is an orally active, selective IGF-1R tyrosine kinase inhibitor with an IC50 of 0.17 μM. NVP-ADW742 inhibits insulin receptor (InsR) with an IC50 of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/proapoptotic biologic sequelae in tumor cells.
-
IGF-I (30-41)
0 ImagesCat. No.: HY-P1773CAS No.: 82177-09-1Synonyms: Insulin-like Growth Factor I (30-41)IGF-I (30-41) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions).
-
Centpiperalone
0 ImagesCat. No.: HY-W207669CAS No.: 22587-11-7Centpiperalone is an orally active hypoglycemic agent. Centpiperalone mainly achieves its hypoglycemic effect by promoting the release of insulin by pancreatic β cells. Centpiperalone can effectively lower blood sugar levels in both normal and diabetic animals. Centpiperalone can be used in research on diabetes.
-
Insulin eflivet
0 ImagesCat. No.: HY-P992087Insulin eflivet is a recombinant antibody targeting insulin receptor. Insulin eflivet can be used in diabetes research.
-
GIP (1-39)
0 ImagesCat. No.: HY-103545CAS No.: 725474-97-5Synonyms: Gastric inhibitory peptide (1-39) (porcine)GIP (1-39) (Gastric inhibitory peptide (1-39) (porcine)) is an insulinotropic peptide that stimulats insulin secretion from rat pancreatic islets. GIP (1-39) at 100 nM was able to significantly increase intracellular Ca2+ concentration ([Ca2+]i), and capable of enhancing exocytosis.
-
DDN
0 ImagesCat. No.: HY-138842CAS No.: 118006-14-7DDN is a selective insulin receptor (Insulin Receptor) activator, an insulin sensitizer, and a glucose-lowering insulin mimetic with oral bioavailability. DDN can directly bind to the receptor kinase domain and induce Akt and ERK phosphorylation, and it can also enhance insulin's effect on glucose uptake. DDN significantly reduces blood glucose levels in wild-type and diabetic ob/ob and db/db mice.
-
BCTC (Standard)
0 ImagesBCTC (Standard) is the analytical standard of BCTC. This product is intended for research and analytical applications. BCTC is an orally active current inhibitor of vanilloid receptor type 1 (VR1). BCTC is a transient receptor potential cation channel subfamily M member 8 (TRPM8) and transient receptor potential vanilloid 1 (TRPV1) antagonist. BCTC is an insulin sensitizer and secretor. BCTC has anticancer and analgesic effects.
-
BMS-754807 (Standard)
0 ImagesCat. No.: HY-10200RCAS No.: 1001350-96-4BMS-754807 (Standard) is the analytical standard of BMS-754807 (HY-10200). This product is intended for research and analytical applications. BMS-754807 is a potent and reversible IGF-1R/IR inhibitor (IC50=1.8 and 1.7 nM, respectively; Ki=<2 nM for both). BMS-754807 also shows potent activities against Met, RON, TrkA, TrkB, AurA, and AurB with IC50 values of 6, 44, 7, 4, 9, and 25 nM, respectively.
-
BMS-554417
0 ImagesCat. No.: HY-10263CAS No.: 468741-42-6BMS-554417 is an orally active inhibitor of insulin receptor and insulin-like growth factor-I receptor (IGF-1R) kinases, with IC50 values of 50.6 nM and 67.9 nM, respectively. BMS-554417 blocks downstream signal transduction via the ERK and PI3K/Akt pathways. BMS-554417 induces G0-G1 cell cycle arrest, prevents cyclin D1 accumulation in the nucleus, triggers mitochondrial pathway-mediated apoptosis, promotes HER2 phosphorylation, and inhibits the proliferation and growth of cancer cells. BMS-554417 can be used in research related to colon cancer, ovarian cancer, and breast cancer.
